Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis.
Journal: Journal of medical economics
Published: June 21, 2026
A Narrative Review of the Immunomodulatory Effects of Acthar® Gel Beyond Its Steroidogenic Properties.
Journal: Advances in therapy
Published: May 06, 2025
Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design.
Journal: Therapeutic advances in neurological disorders
Published: December 12, 2023
Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence.
Journal: Clinical drug investigation
Published: August 23, 2023
Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse.
Journal: Neurodegenerative disease management
Published: December 03, 2021
A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
Journal: Frontiers in neurology
Published: August 24, 2020
Intracerebral haemorrhage during alemtuzumab administration.
Journal: The Lancet. Neurology
Published: January 24, 2019
Showing 1-7 of 7
Last Updated: 09/26/2026